Last reviewed · How we verify
non-pegylated liposomal doxorubicin
Non-pegylated liposomal doxorubicin is a chemotherapy medication that works by intercalating DNA strands, thereby inhibiting the progression of the enzyme topoisomerase II and inducing apoptosis in cancer cells.
Non-pegylated liposomal doxorubicin is a chemotherapy medication that works by intercalating DNA strands, thereby inhibiting the progression of the enzyme topoisomerase II and inducing apoptosis in cancer cells. Used for Metastatic breast cancer, Ovarian cancer, Multiple myeloma.
At a glance
| Generic name | non-pegylated liposomal doxorubicin |
|---|---|
| Also known as | Myocet |
| Sponsor | GBG Forschungs GmbH |
| Drug class | anthracycline |
| Target | topoisomerase II |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This process ultimately leads to cell death, making it an effective treatment for various types of cancer. The liposomal formulation helps to reduce the side effects associated with traditional doxorubicin by targeting the drug directly to the tumor site, minimizing exposure to healthy tissues.
Approved indications
- Metastatic breast cancer
- Ovarian cancer
- Multiple myeloma
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea and vomiting
- Mucositis
- Cardiotoxicity
Key clinical trials
- Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) (PHASE3)
- Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer (PHASE2)
- Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma (PHASE3)
- Pegylated Liposomal Doxorubicin (PLD) Versus Active Surveillance for Advanced Soft Tissue Sarcoma Patients Who Had Controlled Disease After Standard Anthracycline-based Treatment (MELODY) (PHASE2)
- Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma (PHASE3)
- Study Investigating the Cardiotoxicity of Anthracyclines in Patients With Diffuse Large B-Cell
- Adjuvant Systemic Treatment for (ER)-Positive HER2-negative Breast Carcinoma in Women Over 70 According to Genomic Grade (GG): Chemotherapy + Endocrine Treatment Versus Endocrine Treatment (PHASE3)
- ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- non-pegylated liposomal doxorubicin CI brief — competitive landscape report
- non-pegylated liposomal doxorubicin updates RSS · CI watch RSS
- GBG Forschungs GmbH portfolio CI